Galani, Irene http://orcid.org/0000-0001-6455-9848
,
Souli, Maria
Nafplioti, Konstantina
Adamou, Panagiora
Karaiskos, Ilias
Giamarellou, Helen
Antoniadou, Anastasia
Funding for this research was provided by:
MSD - Merck Sharp & Dohme, Hellas (NA)
Article History
Received: 18 December 2018
Accepted: 15 February 2019
First Online: 1 March 2019
Change Date: 29 April 2019
Change Type: Correction
Change Details: The publisher regrets that the article has been published online on 01 March 2019 with errors in Table 1. In the originally published Table 1, the percentage of Imipenem-relebactam susceptibility was incorrectly written as 8 0, while correct data is 98.0. Also, in Meropenem row, column MIC<Subscript>50</Subscript> (mg/L), the incorrect data 4 should be 64.
Compliance with ethical standards
:
: IG has received research grand and speaker honorarium from ACHAOGEN and speaker honorarium and financial support for attending symposia from MSD; MS has received research grand from ACHAOGEN; HG has received research grand from Pfizer; AA has received research grand by MSD. All other authors: none to declare.
: This article does not contain any studies with human participants or animals performed by any of the authors.
: For this type of study, formal consent is not required.
: The funding company did not participate in the study design, data collection, analysis, or, interpretation of data preparation of the manuscript, and the decision to submit the manuscript for publication.